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Abstract
Background—The coronary artery calcium (CAC) score predicts coronary heart disease (CHD)
events, but methods for interpreting the score in combination with conventional CHD risk factors
have not been established.
Methods and Results—We analyzed CAC scores and CHD risk factor measurements from
6757 Black, Chinese, Hispanic and white men and women aged 45–84 years in the Multi-Ethnic
Study of Atherosclerosis (MESA). CAC was associated with age, sex, race-ethnicity, and all
conventional CHD risk factors. Multivariable models using these factors predicted the presence of
CAC (C-statistic = 0.789) and degree of elevation (16% of variation explained), and can be used
to update a “pre-test” CHD risk estimate, such as the 10-year Framingham Risk Score, that is
based on an individual’s conventional risk factors. In scenarios where a high CAC score is
expected, a moderately elevated CAC score of 50 is reassuring (e.g., reducing risk from 10% to
6% in a healthy older white man); but when a low/zero CAC score is expected, even with identical
pre-test CHD risk, the same CAC score of 50 may be alarmingly high (e.g., increasing risk from
10% to 20% in a middle-aged black woman with multiple risk factors). Both the magnitude and
direction of the shift in risk varied markedly with pre-test CHD risk and with the pattern of risk
factors.
Conclusions—Knowing what CAC score to expect for an individual patient, based on their
conventional risk factors, may help clinicians decide when to order a CAC test and how to
interpret the results.
Keywords
coronary disease; calcium; imaging; epidemiology
Correspondence: Mark J. Pletcher, MD, MPH, Department of Epidemiology and Biostatistics, University of California, San Francisco,
185 Berry Street, Suite 5700, San Francisco, CA 94107, Phone: 415-514-8008, Fax: (415-514-8150, mpletcher@epi.ucsf.edu.
Conflict of Interest Disclosures: None.
NIH Public Access
Author Manuscript
Circulation. Author manuscript; available in PMC 2014 September 03.
Published in final edited form as:














Coronary artery calcium (CAC) testing may be useful for guiding interventions to prevent
coronary heart disease (CHD)1. CAC scores predict risk for CHD events2, and higher risk
individuals are more likely to benefit from prevention interventions such as aspirin and
statins3. It is not always clear, however, how clinicians should integrate information from
the CAC score with what they already know about a patient’s CHD risk and other
characteristics. Prior studies have demonstrated strong associations between CAC and a
patient’s age and sex4, 5, race-ethnicity5, and other CHD risk factors such as smoking, blood
pressure, diabetes, and cholesterol6, 7. Given these associations, these individual
characteristics should influence what CAC score a clinician expects when he or she orders
the test in clinical practice. When the actual score is higher than expected, estimates of CHD
risk should logically be revised upwards for that patient, and vice versa when the actual
score is lower than expected. How the clinician interprets the CAC score and estimates the
“post-test” CHD risk, therefore, should depend both on the pre-test risk8 and on a careful
analysis of the expected CAC score (i.e., the “prevalence”9 of CAC) in that patient, but
methods for integrating risk information from the CAC score with conventional CHD risk
factors have not been established. One previous analysis described expected CAC score
distributions and relevant methods, but used a convenience sample of clinic patients of
unknown race/ethnicity who were referred or self-referred for CAC testing, and only self-
reported risk factor data were available7.
The Multi-Ethnic Study of Atherosclerosis (MESA) provides an ideal opportunity to
examine CAC score distributions in a multi-ethnic community-based sample of research
participants who have also undergone careful measurement of conventional CHD risk
factors. Previous analyses of this dataset have yielded widely referenced estimates of the
value of the CAC score in terms of predicting future clinical events2, 10. We used results
from the baseline MESA examination to estimate associations between the CAC score and
conventional CHD risk factors and produce methods for 1) estimating how likely different
CAC scores are in a given clinical scenario, and 2) combining the information from the
CAC score with the patient’s characteristics and a “pre-test” risk estimate to obtain an
integrated “post-test” estimate of CHD risk.
METHODS
Study Sample
MESA is a prospective cohort study of 6814 persons aged 45 to 84 years without known
cardiovascular disease at baseline. Participants were recruited from 6 US cities from July
2000 through September 2002 and identified themselves as white (38%), black (28%),
Hispanic (22%), or Chinese (12%) at the time of enrollment. The study was approved by the
institutional review boards of each site, and all participants gave written informed consent.
The study design has been described in detail elsewhere11. Our analysis uses only cross-
sectional data from the MESA baseline examination.
The Coronary Artery Calcium (CAC) Score
Carr et al reported the details of the MESA CT scanning and interpretation methods12.
Scanning centers assessed coronary calcium by chest computed tomography (CT) with
either a cardiac-gated electron-beam CT scanner (Chicago, Illinois; Los Angeles, California;
and New York, New York field centers) or a multidetector CT system (Baltimore,
Maryland; Forsyth County, North Carolina; and St Paul, Minnesota field centers). Certified
technologists scanned all participants twice over phantoms of known physical calcium
concentration. A radiologist or cardiologist read all CT scans at a central reading center (Los
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Angeles Biomedical Research Institute at Harbor– UCLA, Torrance, California). We used
the mean Agatston score for the 2 scans in all analyses13. Intraobserver and interobserver
agreements were excellent (Kappa=0.93 and 0.90, respectively).
Conventional Coronary Heart Disease (CHD) Risk Factors
The primary predictors in our analysis were race/ethnicity and conventional CHD risk
factors including age, sex, blood pressure level and medication use, cholesterol (total and
high-density lipoprotein (HDL)), diabetes, and smoking status. These measurements were
collected as part of the baseline examination. Blood pressure was measured 3 times using a
Dinamap Pro 1000 automated oscillometric sphygmomanometer (Critikon, Tampa, Florida)
with the participant in a seated position; the mean of the last 2 blood pressure measurements
was used. Total and high-density lipoprotein cholesterol, triglycerides, and plasma glucose
were measured from blood samples obtained after a 12-hour fast. Diabetes was defined as a
fasting plasma glucose level greater than 126 mg/dl (7.8 mmol/L) or a history of medical
treatment for diabetes.
We used the National Cholesterol Education Panel’s Adult Treatment Panel III (ATPIII)
guidelines3 version of the Framingham risk score (FRS) to estimate 10-year risk of CHD
events using measurements obtained during the MESA research exam. For diabetics, we
multiplied the FRS by 1.5 in men and by 1.8 in women, consistent with other published
Framingham risk equations14. We used this score, without recalibration for race/ethnicity or
otherwise, as the “pre-test CHD risk” as recommended in current guidelines3. An alternate
version of our analysis using 5-year risk with recalibration for race-ethnicity using published
data15 is provided in the Supplementary Material.
Statistical Analysis
The CAC score distribution is highly skewed and is very frequently zero, and hence is not
amenable to a simple normalizing transformation, as noted by others16. After exclusion of
zero values, the log-transformed CAC score is approximately normally distributed (Figure).
This leads naturally to a two-stage approach to modeling the CAC score distribution, with
logistic regression (any CAC vs. none) and then linear regression of the log-transformed
CAC score among persons with a non-zero score. This approach allows for parametric
multivariable modeling of the CAC score distribution. As in previous analyses7, the two-
stage approach outperforms alternate one-stage methods (Supplemental Figure).
After describing the study sample, we analyzed the expected distribution of the CAC score
using the two-step approach described above. We used three pre-specified modeling
approaches: 1) using the FRS as the only predictor; 2) using age and sex as the only
predictors; and 3) testing a variety of models considering age, sex/race/ethnicity, the
conventional CHD risk factors used in the FRS, and diabetes. To refine our model without
overfitting, we undertook an unbiased systematic model selection process with 10-fold
cross-validation17, considering all possible models that included all the predictors, up to two
pairwise interactions (0, 1 or 2), and up to 1 quadratic term (0 or 1) for each continuous
variable. The top-performing models in terms of discrimination (cross-validated C-statistic
in the logistic regression model, rounded to 3 significant digits) were identified; among
these, we chose the simplest for presentation. We then used the same predictors in the
second step (linear regression), and present the 10-fold cross-validated R2 value as an
optimism-corrected measure of model performance.
Using these models, we calculated the estimated prevalence of a CAC score in the ranges of
0, 1–100, 101–300, and >300. These categories (or similar ones) have been used in
publications describing the value of the CAC score in terms of predicting future clinical
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events2, 7, 18–20, and represent a simple and clinically important scheme for understanding
the CAC score. The prevalence of scores in each of these categories is described according
to clinical characteristics using the model parameters estimated as above.
As a final step, we used a simple algebraic calculation to combine risk information from
conventional CHD risk factors with information from the CAC score. We assumed that the
“pre-test risk” (using the FRS3 for this illustration) represents an average of persons with
different CAC scores, weighted by the probability of having a CAC score in each category
(calculated according to modeling approach 3, described above). The risks in each category
(annualized) were assumed to differ according to the adjusted relative risk estimates from
Detrano et al2: CAC=0: Reference; CAC=1–100: 3.61; CAC=101–300: 7.73; CAC>300:
9.67. With these assumptions, the “post-test risk” (using information from both the
conventional risk factors and the CAC score) can be calculated algebraically. A variety of
examples are presented, and an Excel-based calculator that can be used to estimate post-test
risk in other clinical scenarios is published in the Online Materials.
RESULTS
The MESA baseline examination included 6814 participants, all of whom had coronary
calcium measured; 57 participants (<1%) were excluded because they were missing either
total or HDL cholesterol, systolic blood pressure, diabetes, or smoking status, leaving 6757
participants for this analysis. Of these, 27% were African-American (black), 12% were
Chinese, 22% were Hispanic, and 39% were non-Hispanic European-American (white);
approximately half were women (52%). Clinically relevant differences were apparent across
race-ethnicity in systolic blood pressure, diabetes, and smoking (Table 1). Despite identical
median FRS’s across race-ethnicity, the prevalence of CAC was significantly different (p<.
001), with the highest prevalence of CAC in non-Hispanic white participants. Age, sex and
race-ethnicity were all strong predictors of the presence and extent of CAC, and the
distributions of log-transformed positive scores were approximately normal (Figure).
The FRS is a strong predictor of CAC (Table 2, Model 1). For each increase of 5% in the
10-year risk for CHD events, the odds of having a positive CAC score nearly doubled (odds
ratio (OR) = 1.80, 95% confidence interval (CI): 1.72–1.89) and the CAC score increased by
32% (95%CI: 28%–36%) among persons with CAC. The C-statistic, a measure of how well
the model discriminates between persons with and without CAC, was .752 (cross-validated).
A second model containing only age and sex performed better (cross-validated C-statistic = .
767; Table 2, Model 2).
A model adjusting for age, sex, race-ethnicity and conventional risk factors provided the
best discrimination (cross-validated C-statistic .789) and explained the most variation in the
CAC score (cross-validated R2 = .160; Table 2, Model 3). In a systematic model selection
procedure, the model that used the individual predictor variables from the FRS (including an
interaction between systolic blood pressure and use of blood pressure medications), as well
as race-ethnicity and diabetes, performed as well or better than models containing additional
interactions or nonlinear terms for continuous variables (i.e., no alternatives scored a C-
statistic higher than 0.789). Even with adjustment for conventional CHD risk factors, race-
ethnicity was a highly significant predictor of CAC; a similar model not including race-
ethnicity did not perform as well (cross-validated C-statistic = .778, Supplemental Table in
Online Materials). Stratification by race-ethnicity (achieved by inclusion of all pairwise
interactions for race-ethnicity with other predictors in the model) did not result in better
performance (cross-validated C-statistic = .788); stratification by diabetes status or by sex
led to similar results (cross-validated C-statistic = .787 and .788, respectively).
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The predicted CAC distribution varied markedly by characteristics of the individual (Table
3). The expected distribution of CAC shifts towards higher scores with increasing FRS
(Table 3, panel 1) and even more so with male gender and higher age. For example, the
probability of CAC = 0 decreases from 89% in 45 year-old women to 6% in 85 year-old men
(Table 3, panel 2). Adding race/ethnicity and using the individual CHD risk factor
measurements (instead of the overall FRS) along with age and sex (i.e., Model 3) yields
personalized CAC score predictions for any given clinical scenario (examples shown in
Table 3, panel 3).
The interpretation of these CAC scores must also be individualized. By integrating the
personalized CAC score prediction with the pre-test risk, as from FRS, post-test risk
estimates for each CAC score category can be obtained, and these differ sharply across
scenarios (Table 4). While a CAC score of zero is generally reassuring (Table 4, all
examples), a very high CAC score increases post-test risk only a little when pre-test risk is
low (examples 1 and 2). Even more striking is the interpretation of an intermediate score
(CAC = 1–100), which is remarkably different across scenarios. For example, in a white
man without CHD risk factors, a CAC score of 50 reassuringly reduces the post-test risk
estimate (example 7), while in a 55 year old Hispanic woman with many CHD risk factors,
the same CAC score would predict an elevation in post-test risk (example 10). Even when
pre-test 10-year CHD risk is held constant, such as at 10% (examples 5–7), post-test risk
varies markedly depending on the pattern of risk factors. In the elderly white man without
risk factors who achieves his pre-test of risk of 10% by virtue of his age alone, even a high
CAC score > 100, or even > 300, is quite likely and not overly worrisome (example 7); but
in a black woman who achieves her pre-test risk of 10% because of her adverse CHD risk
factor profile, a CAC score over 100 would be very rare, and a score between 1–100 would
be alarmingly high (example 5). In a middle-aged Hispanic man with a CHD risk of 10%,
CAC = 1–100 changes pre-test risk only slightly, while any CAC score over 100 would be
concerning (example 6). Note that in all of these “intermediate risk” cases, the likelihood of
obtaining a CAC score that might either reassure (post-test risk < 5%) or raise concern (post-
test risk > 20%) is relatively high. In patients with high pre-test risk (examples 10 and 11),
the likelihood of obtaining a score indicating a post-test risk ≤ 10%, which might decrease
the urgency or aggressiveness of preventive therapies, is also moderately high. The Excel-
based calculator provided in the Supplemental Materials can be used to obtain these
estimates for any given combination of risk factors.
DISCUSSION
We show here that the distribution and interpretation of the CAC score is critically
dependent on individual characteristics of the patient. Interpretation of the measured CAC
score differs sharply in different clinical scenarios, even when the overall pre-test CHD risk
is similar. It is not enough to know that a patient is “intermediate risk”; one must also have
information about which risk factors led to that designation in order to interpret the CAC
score. The methods and estimates provided here provide powerful “personalized”
predictions that can help clinicians decide when to order a CAC scan and how to interpret
the results in order to optimize targeting of CHD prevention interventions.
Our finding that CAC is related to conventional CHD risk factors is consistent with prior
studies that consistently demonstrate associations between CAC and conventional risk
factors, including age and sex4, 5 as well as blood pressure, lipids, diabetes and smoking6, 7.
No prior studies have shown an association between blood pressure medication use and
CAC, but this relationship is presumably mediated by past longterm exposure to higher
average blood pressure, and prior studies have shown strong relationships between
cumulative lifetime exposure to cardiovascular risk factors and CAC21, 22. The relationship
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with race-ethnicity has also been described5. Unlike prior studies showing the general
relationship between the overall FRS and CAC23, we demonstrate here that fitting the CAC
score against the individual component CHD risk factor measurements, along with race-
ethnicity, provides more accurate CAC score predictions (even when subjected to cross-
validation) than using the overall FRS without refitting the components. Our multivariable
models provide estimates of the independent associations between risk factors and coronary
calcium, as well as a more accurate method for estimating the expected distribution of CAC
in any given clinical setting.
The findings are generally consistent with Bayesian reasoning and risk reclassification
theory1, 8, 24, 25, which suggest that CAC testing may be most useful for persons who start
out as having an “intermediate risk” for CHD. In the examples we provide, the likelihood of
obtaining a CAC score that might change management (i.e., pushing it outside of a putative
“gray zone” between 5%–20% 10-year risk) is highest in persons with an intermediate pre-
test CHD risk (Table 4, examples 5–7, and also 3–4 and 8–9), and is very low in persons
who are at very low pre-test risk (examples 1–2). Prior analyses of MESA focusing on
reclassification methodology provide empiric evidence for the relatively high
reclassification rates we project in our analyses10. Our analyses also project a relatively high
rate of downwards reclassification of risk among persons who start off with high CHD risk
(examples 10–11), consistent with prior reports of the high negative predictive value of a
CAC score of 08, 26, 27.
Unlike prior studies, however, our analysis highlights how important it is to “personalize”
the interpretation of the CAC score. While prior studies reported differences in post-test risk
for different CAC scores2, they did not compare post-test risk with pre-test risk. Our
analyses show that post-test risk changes a different amount in different patients, and
sometimes even in the opposite direction, as illustrated most clearly for a CAC score of 1–
100 in Table 4 (examples 3, 5 and 8 vs. 7, 9 and 11). The critical factor determining how
risk changes from pre- to post-test, as reported theoretically by prior investigators9, is how
the actual test result compares with the expected test result in the individual patient (i.e., the
conditional “prevalence”9 of that test result). Simply stated, a given test result (e.g., CAC =
50) may be either higher or lower than expected, and the risk estimate should logically shift
higher or lower in accordance. By carefully defining the expected test result distribution for
a patient, individualized using that patient’s risk factor measurements, we can optimally
“personalize” the interpretation of that patient’s CAC score and quantify the expected shift
from pre- to post-test in that patient.
No prior studies have presented methods for estimating the expected distribution of the CAC
score in any given clinical setting that accounts for both demographic factors (including
race-ethnicity) and carefully measured conventional CHD risk factors. The MESA Arterial
Age Calculator28 provides CHD risk estimates that use CAC, but they don’t account for the
strong correlations between risk factors (other than age) and CAC. In a prior publication7,
we presented methods and results similar to what we present here, but that analysis used a
convenience sample of patients referred in a clinical context (or self-referred) for a CAC
score measurement, and the only information on conventional CHD risk factors was self-
reported presence or absence (no continuous measurements). No race-ethnicity information
was available. Unlike our prior report, the current results use high-quality measurements of
CHD risk factors, take into account degree of elevation (e.g., for blood pressure or
cholesterol), and account for the strong effects of race-ethnicity.
Our analysis is subject to a number of important limitations. MESA is a community-based
sample including 6 US cities across the country; but it is still possible that participants in the
study were not perfectly representative of the US population. For example, research
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participants are known to be healthier on average than non-participants. While measures of
association are relatively robust to this type of selection pressure, the intercepts for our
models (which determine overall average prevalence/score) might be subject to selection
bias and lower than the average for the population.
Similarly, the FRS pre-test CHD risk estimates used for illustration in Table 4 (and thus the
corresponding post-test estimates in that same table) may not always be generalizable given
that it was derived from the all-white Framingham study cohort. Methods and estimates
required for “recalibration” have been published15. We used these methods to calculate
recalibrated 5-year CHD risk scores for race-sex groups for which this is possible, and
present an alternate version of Table 4 in the Supplemental Material (Supplemental Table 2;
other results are unaffected). Other such substitutions are easily accomplished, and a “user-
defined” pre-test risk option is provided in the Excel calculator provided in the
Supplemental Material.
Our method of using the CAC score together with conventional CHD risk factors (Table 4)
depends on the assumption that the relative risk for CHD associated with different levels of
CAC2 is constant across different participant characteristics. For example, the relative risk
of 7.73 for a person with a CAC score of 200 vs. a CAC score of 0 is assumed to hold for
both young healthy women and for older men with risk factors. While there is evidence that
CAC is very predictive across categories of race/ethnicity2, age29, and overall CHD risk30,
systematic testing for and quantification of this type of interaction have not been conducted.
These results represent an attempt at producing a clinically-relevant method for using the
CAC score in clinical practice. Our results should help clinicians make the decision about
when the test is likely to yield actionable results, and how to interpret the CAC score in the
light of the patient’s individual risk profile based on their conventional CHD risk factors.
The post-test risk estimate can then be used (in place of the pre-test risk estimate) as a more
“personalized” guide for how aggressive to be with interventions to prevent the onset of
clinical CHD. The net comparative effectiveness and efficiency (cost-effectiveness) of this
approach, however, have not been proven. To do so would require randomized controlled
trials of an integrated screening and targeted prevention strategy31 or careful modeling of
expected benefits, harms and costs32.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The coronary artery calcium (CAC) score is a strong predictor of coronary heart disease
(CHD) events, but it is not always clear how to interpret the score in the context of a
patient’s conventional CHD risk factors like blood pressure, cholesterol, smoking status,
etc. This analysis of the Multi-Ethnic Study of Atherosclerosis (MESA) provides a way
for clinicians to use conventional CHD risk factor information about a patient to
understand how high a CAC score to expect. When the actual score is higher than
expected, a clinician’s estimate of that patient’s CHD risk (the “pre-test” risk, for
example from Framingham equations), should be adjusted upwards; if it is lower than
expected, the clinician’s estimate should be revised downwards. This article describes a
method for making this adjustment, and provides examples illustrating the importance of
individualized interpretation of the CAC score. These methods may be useful for
clinicians deciding when to order a CAC score and how to interpret the results.
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Distribution of coronary artery calcium scores among men and women, on a logarithmic
scale, by age and by race/ethnicity. Categories chosen for histograms are evenly spaced on a
logarithmic scale, corresponding to Ln(CAC) scores of <1, 1–2, 2–3, 3–4, 4–5, 5–6, 6–7, 7–
8, and >8. The first bar represents subjects with no detectable CAC, which corresponds to an
undefined Ln(CAC) value. CAC – Coronary artery calcium
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Table 1
Characteristics of MESA participants
Characteristic
Race/Ethnicity
Black Chinese-American Hispanic/Latino White, Non-Hispanic
N (%), mean ± SD, or median (IQR) N=1859 N=800 N=1494 N=2604
Age, years 62 +/− 10 62 +/− 10 61 +/− 10 63 +/− 10
Sex, n (%) women 1027 (55%) 413 (52%) 773 (52%) 1354 (52%)
Systolic blood pressure, mmHg 132 +/− 22 125 +/− 22 127 +/−22 123 +/− 20
Total cholesterol, mg/dl 190 +/− 36 193 +/− 32 198 +/− 37 196 +/− 35
HDL cholesterol, mg/dl 52 +/− 15 50 +/− 13 48 +/− 13 52 +/− 16
Diabetes mellitus, n (%) 326 (18%) 105 (13%) 264 (18%) 158 (6%)
Current smoker, n (%) 333 (18%) 45 (6%) 203 (14%) 299 (11%)
FRS* 10-year CHD risk, median % (IQR) 6% (2%–14%) 6% (2%–13%) 6% (2%–14%) 6% (2%–13%)
Coronary calcium present, n (%) 813 (44%) 402 (50%) 676 (45%) 1485 (57%)
*
- The Framingham Risk Score, from National Cholesterol Education Program’s Adult Treatment Panel (ATPIII) guidelines3, with adjustment for
diabetes status (see Methods).
MESA – Multi-Ethnic Study of Atherosclerosis; SD – Standard deviation; HDL – High-density lipoprotein; IQR – Inter-quartile range; FRS –
Framingham Risk Score; CHD – Coronary heart disease
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